SKYRIZI
SKYRIZI can help control symptoms for Plaque Psoriasis, Psoriatic Arthritis and Chron’s Disease.
Administration and Dosage:
Plaque Psoriasis and Psoriatic Arthritis:
• 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
• In patients with psoriatic arthritis SKYRIZI can be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs
Crohn’s Disease:
• Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI.
The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.
Indication:
SKYRIZI is a prescription medicine used to treat adults with:
- moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy)
- active psoriatic arthritis (PsA)
- moderate to severe Crohn’s disease
Common Side Effects:
The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, injection site reactions, fever, headache, stomach (abdominal) pain, back pain, joint pain, and low red blood cells (anemia). The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include upper respiratory infections, feeling tired, fungal skin infections, headache, and injection site reactions.
More information:
Please see full Prescribing Informationand Medication Guide including Patient Information.
HAVE QUESTIONS?
